10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30106% above fair value
$56.30+1.31 (+2.38%)
Close on Nov 17, 2026Market cap $7.34BP/E –Yield –
10x Genomics r&d expenses
Research and development expenses are spending on new products and technology.
10x Genomics's R&D Expenses for the twelve months ending Sep 30, 2026 was $222.54M, down 10.9% year over year. For fiscal 2025 it was $238.63M, down 9.8% from the year before. The highest annual figure on record is $270.33M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.63M | -9.8% |
| FY2024 | Dec 31, 2024 | $264.70M | -2.1% |
| FY2023 | Dec 31, 2023 | $270.33M | +1.8% |
| FY2022 | Dec 31, 2022 | $265.67M | +25.5% |
| FY2021 | Dec 31, 2021 | $211.75M | +71.6% |
| FY2020 | Dec 31, 2020 | $123.38M | +48.5% |
| FY2019 | Dec 31, 2019 | $83.10M | +74.8% |
| FY2018 | Dec 31, 2018 | $47.54M | +47.8% |
| FY2017 | Dec 31, 2017 | $32.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $52.93M | -7.5% |
| Q2 FY2026 | Jun 30, 2026 | $56.79M | -7.2% |
| Q1 FY2026 | Mar 31, 2026 | $56.85M | -11.5% |
| Q4 FY2025 | Dec 31, 2025 | $55.97M | -16.4% |
| Q3 FY2025 | Sep 30, 2025 | $57.19M | -13.6% |
| Q2 FY2025 | Jun 30, 2025 | $61.22M | -2.7% |
| Q1 FY2025 | Mar 31, 2025 | $64.25M | -6.4% |
| Q4 FY2024 | Dec 31, 2024 | $66.97M | +2.6% |
| Q3 FY2024 | Sep 30, 2024 | $66.17M | -0.5% |
| Q2 FY2024 | Jun 30, 2024 | $62.92M | -12.0% |
| Q1 FY2024 | Mar 31, 2024 | $68.64M | +2.3% |
| Q4 FY2023 | Dec 31, 2023 | $65.27M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $66.51M | -1.2% |
| Q2 FY2023 | Jun 30, 2023 | $71.46M | +1.1% |
| Q1 FY2023 | Mar 31, 2023 | $67.10M | +4.7% |
| Q4 FY2022 | Dec 31, 2022 | $63.61M | +2.8% |
| Q3 FY2022 | Sep 30, 2022 | $67.29M | +23.3% |
| Q2 FY2022 | Jun 30, 2022 | $70.69M | +32.4% |
| Q1 FY2022 | Mar 31, 2022 | $64.08M | +53.0% |
| Q4 FY2021 | Dec 31, 2021 | $61.89M | +55.9% |
| Q3 FY2021 | Sep 30, 2021 | $54.58M | +81.1% |
| Q2 FY2021 | Jun 30, 2021 | $53.40M | +93.9% |
| Q1 FY2021 | Mar 31, 2021 | $41.88M | +61.1% |
| Q4 FY2020 | Dec 31, 2020 | $39.71M | +42.4% |
| Q3 FY2020 | Sep 30, 2020 | $30.14M | +35.7% |
| Q2 FY2020 | Jun 30, 2020 | $27.54M | +52.7% |
| Q1 FY2020 | Mar 31, 2020 | $25.99M | +73.7% |
| Q4 FY2019 | Dec 31, 2019 | $27.89M | +113.2% |
| Q3 FY2019 | Sep 30, 2019 | $22.21M | +100.4% |
| Q2 FY2019 | Jun 30, 2019 | $18.03M | – |
| Q1 FY2019 | Mar 31, 2019 | $14.97M | – |
| Q4 FY2018 | Dec 31, 2018 | $13.08M | – |
| Q3 FY2018 | Sep 30, 2018 | $11.09M | – |
See a number that looks wrong?